Cardio-ankle  ||| S:0 E:13 ||| JJ
vascular  ||| S:13 E:22 ||| JJ
index  ||| S:22 E:28 ||| NN
( ||| S:28 E:29 ||| -LRB-
CAVI ||| S:29 E:33 ||| NNP
)  ||| S:33 E:35 ||| -RRB-
and  ||| S:35 E:39 ||| CC
cardiovascular  ||| S:39 E:54 ||| JJ
disease  ||| S:54 E:62 ||| NN
Increased  ||| S:62 E:72 ||| VBN
arterial  ||| S:72 E:81 ||| JJ
stiffness  ||| S:81 E:91 ||| NN
is  ||| S:91 E:94 ||| VBZ
closely  ||| S:94 E:102 ||| RB
associated  ||| S:102 E:113 ||| VBN
with  ||| S:113 E:118 ||| IN
the  ||| S:118 E:122 ||| DT
progression  ||| S:122 E:134 ||| NN
of  ||| S:134 E:137 ||| IN
cardiovascular  ||| S:137 E:152 ||| JJ
disease ||| S:152 E:159 ||| NN
.  ||| S:159 E:161 ||| .
A  ||| S:161 E:163 ||| DT
novel  ||| S:163 E:169 ||| NN
blood-pressure  ||| S:169 E:184 ||| JJ
independent  ||| S:184 E:196 ||| JJ
arterial  ||| S:196 E:205 ||| JJ
stiffness  ||| S:205 E:215 ||| JJ
parameter ||| S:215 E:224 ||| NN
,  ||| S:224 E:226 ||| ,
the  ||| S:226 E:230 ||| DT
cardio-ankle  ||| S:230 E:243 ||| JJ
vascular  ||| S:243 E:252 ||| JJ
index  ||| S:252 E:258 ||| NN
( ||| S:258 E:259 ||| -LRB-
CAVI ||| S:259 E:263 ||| NNP
) ||| S:263 E:264 ||| -RRB-
,  ||| S:264 E:266 ||| ,
has  ||| S:266 E:270 ||| VBZ
been  ||| S:270 E:275 ||| VBN
developed  ||| S:275 E:285 ||| VBN
and  ||| S:285 E:289 ||| CC
is  ||| S:289 E:292 ||| VBZ
used  ||| S:292 E:297 ||| VBN
worldwide ||| S:297 E:306 ||| NN
.  ||| S:306 E:308 ||| .
Arterial  ||| S:308 E:317 ||| NNP
stiffness  ||| S:317 E:327 ||| VBD
derived  ||| S:327 E:335 ||| VBN
using  ||| S:335 E:341 ||| VBG
CAVI  ||| S:341 E:346 ||| NNP
in  ||| S:346 E:349 ||| IN
healthy  ||| S:349 E:357 ||| JJ
subjects  ||| S:357 E:366 ||| NNS
increases  ||| S:366 E:376 ||| VBZ
linearly  ||| S:376 E:385 ||| VBN
with  ||| S:385 E:390 ||| IN
aging ||| S:390 E:395 ||| VBG
,  ||| S:395 E:397 ||| ,
and  ||| S:397 E:401 ||| CC
is  ||| S:401 E:404 ||| VBZ
higher  ||| S:404 E:411 ||| JJR
in  ||| S:411 E:414 ||| IN
men  ||| S:414 E:418 ||| NNS
than  ||| S:418 E:423 ||| IN
in  ||| S:423 E:426 ||| IN
women ||| S:426 E:431 ||| NNS
.  ||| S:431 E:433 ||| .
This  ||| S:433 E:438 ||| DT
is  ||| S:438 E:441 ||| VBZ
a  ||| S:441 E:443 ||| DT
new  ||| S:443 E:447 ||| JJ
finding ||| S:447 E:454 ||| NN
,  ||| S:454 E:456 ||| ,
not  ||| S:456 E:460 ||| RB
observed  ||| S:460 E:469 ||| VBN
with  ||| S:469 E:474 ||| IN
conventional  ||| S:474 E:487 ||| JJ
arterial  ||| S:487 E:496 ||| JJ
stiffness  ||| S:496 E:506 ||| JJ
indicators ||| S:506 E:516 ||| NNS
.  ||| S:516 E:518 ||| .
In  ||| S:518 E:521 ||| IN
patients  ||| S:521 E:530 ||| NNS
with  ||| S:530 E:535 ||| IN
risk  ||| S:535 E:540 ||| NN
factors  ||| S:540 E:548 ||| NNS
such  ||| S:548 E:553 ||| JJ
as  ||| S:553 E:556 ||| IN
hypertension ||| S:556 E:568 ||| NN
,  ||| S:568 E:570 ||| ,
diabetes ||| S:570 E:578 ||| NN
,  ||| S:578 E:580 ||| ,
hypercholesterolemia ||| S:580 E:600 ||| NN
,  ||| S:600 E:602 ||| ,
left  ||| S:602 E:607 ||| VBD
ventricular  ||| S:607 E:619 ||| JJ
hypertrophy ||| S:619 E:630 ||| NN
,  ||| S:630 E:632 ||| ,
chronic  ||| S:632 E:640 ||| JJ
kidney  ||| S:640 E:647 ||| NN
disease  ||| S:647 E:655 ||| NN
and  ||| S:655 E:659 ||| CC
hyperuricemia ||| S:659 E:672 ||| NN
,  ||| S:672 E:674 ||| ,
CAVI  ||| S:674 E:679 ||| NNP
values  ||| S:679 E:686 ||| NNS
are  ||| S:686 E:690 ||| VBP
higher  ||| S:690 E:697 ||| JJR
than  ||| S:697 E:702 ||| IN
in  ||| S:702 E:705 ||| IN
controls ||| S:705 E:713 ||| NNS
.  ||| S:713 E:715 ||| .
Antihypertensive ||| S:715 E:731 ||| NNP
,  ||| S:731 E:733 ||| ,
antidiabetic ||| S:733 E:745 ||| NN
,  ||| S:745 E:747 ||| ,
and  ||| S:747 E:751 ||| CC
antilipemic  ||| S:751 E:763 ||| JJ
medications  ||| S:763 E:775 ||| NNS
are  ||| S:775 E:779 ||| VBP
effective  ||| S:779 E:789 ||| JJ
in  ||| S:789 E:792 ||| IN
lowering  ||| S:792 E:801 ||| VBG
elevated  ||| S:801 E:810 ||| JJ
CAVI ||| S:810 E:814 ||| NNP
.  ||| S:814 E:816 ||| .
Among  ||| S:816 E:822 ||| IN
the  ||| S:822 E:826 ||| DT
antiplatelet  ||| S:826 E:839 ||| JJ
agents ||| S:839 E:845 ||| NNS
,  ||| S:845 E:847 ||| ,
highly  ||| S:847 E:854 ||| RB
purified  ||| S:854 E:863 ||| JJ
eicosapentaenoic  ||| S:863 E:880 ||| JJ
acid  ||| S:880 E:885 ||| NN
( ||| S:885 E:886 ||| -LRB-
EPA ||| S:886 E:889 ||| NNP
)  ||| S:889 E:891 ||| -RRB-
in  ||| S:891 E:894 ||| IN
fish  ||| S:894 E:899 ||| NN
oil  ||| S:899 E:903 ||| NN
has  ||| S:903 E:907 ||| VBZ
the  ||| S:907 E:911 ||| DT
effect  ||| S:911 E:918 ||| NN
of  ||| S:918 E:921 ||| IN
lowering  ||| S:921 E:930 ||| VBG
CAVI ||| S:930 E:934 ||| NNP
.  ||| S:934 E:936 ||| .
It  ||| S:936 E:939 ||| PRP
is  ||| S:939 E:942 ||| VBZ
also  ||| S:942 E:947 ||| RB
useful  ||| S:947 E:954 ||| JJ
in  ||| S:954 E:957 ||| IN
the  ||| S:957 E:961 ||| DT
evaluation  ||| S:961 E:972 ||| NN
of  ||| S:972 E:975 ||| IN
the  ||| S:975 E:979 ||| DT
effects  ||| S:979 E:987 ||| NNS
of  ||| S:987 E:990 ||| IN
lifestyle  ||| S:990 E:1000 ||| JJ
modification ||| S:1000 E:1012 ||| NN
.  ||| S:1012 E:1014 ||| .
It  ||| S:1014 E:1017 ||| PRP
has  ||| S:1017 E:1021 ||| VBZ
been  ||| S:1021 E:1026 ||| VBN
shown  ||| S:1026 E:1032 ||| VBN
that  ||| S:1032 E:1037 ||| IN
CAVI  ||| S:1037 E:1042 ||| NNP
values  ||| S:1042 E:1049 ||| NNS
are  ||| S:1049 E:1053 ||| VBP
elevated  ||| S:1053 E:1062 ||| VBN
even  ||| S:1062 E:1067 ||| RB
with  ||| S:1067 E:1072 ||| IN
mild  ||| S:1072 E:1077 ||| JJ
arteriosclerotic  ||| S:1077 E:1094 ||| JJ
disease ||| S:1094 E:1101 ||| NN
,  ||| S:1101 E:1103 ||| ,
and  ||| S:1103 E:1107 ||| CC
differences  ||| S:1107 E:1119 ||| NNS
in  ||| S:1119 E:1122 ||| IN
the  ||| S:1122 E:1126 ||| DT
degree  ||| S:1126 E:1133 ||| NN
of  ||| S:1133 E:1136 ||| IN
arteriosclerosis  ||| S:1136 E:1153 ||| NNS
can  ||| S:1153 E:1157 ||| MD
be  ||| S:1157 E:1160 ||| VB
estimated  ||| S:1160 E:1170 ||| VBN
between  ||| S:1170 E:1178 ||| IN
patients  ||| S:1178 E:1187 ||| NNS
with  ||| S:1187 E:1192 ||| IN
severe  ||| S:1192 E:1199 ||| JJ
arteriosclerotic  ||| S:1199 E:1216 ||| JJ
disease ||| S:1216 E:1223 ||| NN
,  ||| S:1223 E:1225 ||| ,
for  ||| S:1225 E:1229 ||| IN
example  ||| S:1229 E:1237 ||| NN
those  ||| S:1237 E:1243 ||| DT
with  ||| S:1243 E:1248 ||| IN
ischemic  ||| S:1248 E:1257 ||| JJ
cardiac  ||| S:1257 E:1265 ||| JJ
disease  ||| S:1265 E:1273 ||| NN
and  ||| S:1273 E:1277 ||| CC
dialysis  ||| S:1277 E:1286 ||| NN
patients ||| S:1286 E:1294 ||| NNS
.  ||| S:1294 E:1296 ||| .
In  ||| S:1296 E:1299 ||| IN
coronary  ||| S:1299 E:1308 ||| JJ
artery  ||| S:1308 E:1315 ||| NN
disease ||| S:1315 E:1322 ||| NN
,  ||| S:1322 E:1324 ||| ,
CAVI  ||| S:1324 E:1329 ||| NNP
reflect  ||| S:1329 E:1337 ||| VBP
the  ||| S:1337 E:1341 ||| DT
severity  ||| S:1341 E:1350 ||| NN
of  ||| S:1350 E:1353 ||| IN
the  ||| S:1353 E:1357 ||| DT
diseased  ||| S:1357 E:1366 ||| JJ
coronary  ||| S:1366 E:1375 ||| JJ
artery  ||| S:1375 E:1382 ||| NN
and  ||| S:1382 E:1386 ||| CC
latent  ||| S:1386 E:1393 ||| JJ
plaque  ||| S:1393 E:1400 ||| NN
in  ||| S:1400 E:1403 ||| IN
coronary  ||| S:1403 E:1412 ||| JJ
arteries  ||| S:1412 E:1421 ||| NNS
using  ||| S:1421 E:1427 ||| VBG
intravascular  ||| S:1427 E:1441 ||| JJ
ultrasound  ||| S:1441 E:1452 ||| NN
imaging ||| S:1452 E:1459 ||| NN
( ||| S:1459 E:1460 ||| -LRB-
IVUS ||| S:1460 E:1464 ||| NNP
) ||| S:1464 E:1465 ||| -RRB-
.  ||| S:1465 E:1467 ||| .
It  ||| S:1467 E:1470 ||| PRP
is  ||| S:1470 E:1473 ||| VBZ
also  ||| S:1473 E:1478 ||| RB
reported  ||| S:1478 E:1487 ||| VBN
that  ||| S:1487 E:1492 ||| IN
patients  ||| S:1492 E:1501 ||| NNS
with  ||| S:1501 E:1506 ||| IN
higher  ||| S:1506 E:1513 ||| JJR
CAVI  ||| S:1513 E:1518 ||| NN
values  ||| S:1518 E:1525 ||| NNS
have  ||| S:1525 E:1530 ||| VBP
a  ||| S:1530 E:1532 ||| DT
poor  ||| S:1532 E:1537 ||| JJ
prognosis  ||| S:1537 E:1547 ||| NNS
compared  ||| S:1547 E:1556 ||| VBN
with  ||| S:1556 E:1561 ||| IN
those  ||| S:1561 E:1567 ||| DT
with  ||| S:1567 E:1572 ||| IN
lower  ||| S:1572 E:1578 ||| JJR
CAVI  ||| S:1578 E:1583 ||| NN
values ||| S:1583 E:1589 ||| NNS
.  ||| S:1589 E:1591 ||| .
Its  ||| S:1591 E:1595 ||| PRP$
advantage  ||| S:1595 E:1605 ||| NN
of  ||| S:1605 E:1608 ||| IN
reproducibility ||| S:1608 E:1623 ||| NN
,  ||| S:1623 E:1625 ||| ,
with  ||| S:1625 E:1630 ||| IN
little  ||| S:1630 E:1637 ||| JJ
disparity  ||| S:1637 E:1647 ||| NN
among  ||| S:1647 E:1653 ||| IN
institutions ||| S:1653 E:1665 ||| NNS
,  ||| S:1665 E:1667 ||| ,
has  ||| S:1667 E:1671 ||| VBZ
opened  ||| S:1671 E:1678 ||| VBN
up  ||| S:1678 E:1681 ||| RP
the  ||| S:1681 E:1685 ||| DT
way  ||| S:1685 E:1689 ||| NN
for  ||| S:1689 E:1693 ||| IN
multi-center  ||| S:1693 E:1706 ||| JJ
joint  ||| S:1706 E:1712 ||| JJ
studies ||| S:1712 E:1719 ||| NNS
.  ||| S:1719 E:1721 ||| .
